- Home
- OPAD vs CNTX Comparison
OPAD vs CNTX Comparison
Compare OPAD & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- CNTX
- Stock Information
- Founded
- OPAD 2015
- CNTX 2015
- Country
- OPAD United States
- CNTX United States
- Employees
- OPAD N/A
- CNTX N/A
- Industry
- OPAD Real Estate
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- CNTX Health Care
- Exchange
- OPAD Nasdaq
- CNTX Nasdaq
- Market Cap
- OPAD 89.3M
- CNTX 102.9M
- IPO Year
- OPAD N/A
- CNTX 2021
- Fundamental
- Price
- OPAD $1.99
- CNTX $1.13
- Analyst Decision
- OPAD Hold
- CNTX Strong Buy
- Analyst Count
- OPAD 4
- CNTX 7
- Target Price
- OPAD $2.22
- CNTX $5.40
- AVG Volume (30 Days)
- OPAD 1.3M
- CNTX 299.5K
- Earning Date
- OPAD 11-03-2025
- CNTX 11-05-2025
- Dividend Yield
- OPAD N/A
- CNTX N/A
- EPS Growth
- OPAD N/A
- CNTX N/A
- EPS
- OPAD N/A
- CNTX N/A
- Revenue
- OPAD $627,966,000.00
- CNTX N/A
- Revenue This Year
- OPAD N/A
- CNTX N/A
- Revenue Next Year
- OPAD $31.90
- CNTX N/A
- P/E Ratio
- OPAD N/A
- CNTX N/A
- Revenue Growth
- OPAD N/A
- CNTX N/A
- 52 Week Low
- OPAD $0.91
- CNTX $0.49
- 52 Week High
- OPAD $6.35
- CNTX $1.65
- Technical
- Relative Strength Index (RSI)
- OPAD 42.87
- CNTX 49.75
- Support Level
- OPAD $1.68
- CNTX $1.00
- Resistance Level
- OPAD $2.05
- CNTX $1.16
- Average True Range (ATR)
- OPAD 0.19
- CNTX 0.10
- MACD
- OPAD 0.06
- CNTX -0.00
- Stochastic Oscillator
- OPAD 60.00
- CNTX 54.92
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.